

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902194 CAPLUS Full-text
 DN 141:395590
 TI Preparation of benzoxazepine compounds as RFRP receptor antagonists
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi
 PA Takeda Chemical Industries Ltd., Japan
 SO PCT Int. Appl., 226 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004091628 | A1 | 20041028 | WO 2004-JP5406 | 20040415 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | JP 2004331659 | A | 20041125 | JP 2004-120246 | 20040415 |
| | EP 1623710 | A1 | 20060208 | EP 2004-727766 | 20040415 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | US 2007129348 | A1 | 20070607 | US 2005-553273 | 20051012 |
| PRAI | JP 2003-114313 | A | 20030418 | | |
| | WO 2004-JP5406 | W | 20040415 | | |
| OS | MARPAT 141:395590 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(:O)n, NR₃; n = 0-2; R₃ = H, (un)substituted hydrocarbon group, etc.; R₁, R₂ = H, (un)substituted hydrocarbon group, etc.] were prepared For example, reductive amination of compound trans-II·HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II·HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC₅₀ value was <1 μM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.

IT 782468-62-6F
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-62-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 782467-01-0P 782467-03-2P 782467-53-2P
782467-63-4P 782467-69-0P 782467-75-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-63-4 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

IT 782468-58-0P 782468-60-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[[[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[[[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1050851 CAPLUS Full-text
 DN 143:347212
 TI Preparation of aryl dihydrobenzoxazepinone derivatives as progesterone
 receptor modulators
 IN Zhang, Puwen; Wrobel, Jay Edward; Terefenko, Eugene Anthony; Kern, Jeffrey
 Curtis
 PA Wyeth, John, and Brother Ltd., USA
 SO U.S. Pat. Appl. Publ., 61 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2005215539 | A1 | 20050929 | US 2005-87051 | 20050322 |
| | WO 2005095366 | A1 | 20051013 | WO 2005-US9756 | 20050323 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | | |
| | CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, | | | | |
| | GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, | | | | |
| | LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, | | | | |
| | NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, | | | | |
| | SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | | | | |
| | AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, | | | | |
| | EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, | | | | |
| | RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, | | | | |
| | MR, NE, SN, TD, TG | | | | |
| PRAI | US 2004-555945P | P | 20040324 | | |
| | US 2005-87051 | A | 20050322 | | |
| OS | MARPAT 143:347212 | | | | |
| GI | | | | | |



AB Title compds. I [R1 = H, alkyl or CORA; RA = H, alkyl, alkoxy, etc.; R2 and R3 independently = H, CF3 or alkyl; R4 and R5 independently = H, alkenyl, alkynyl, etc. or together they may form a alkylspirocyclic ring or heterospirocyclic ring; R6 = benzofused heterocyclic ring, substituted Ph or heterocycle; R7 = CN, halo, NO2, etc.; Q = O, S, NR8, etc.; R8 = CN, (un)substituted alkyl, aryl, etc.; X = O, S, NR9, etc.; R9 = H or alkyl with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as progesterone receptor modulators. Thus, e.g., II was prepared by cyclization of N-[4-bromo-2-(1-hydroxy-1-thien-2-ylethyl)phenyl]- 2-chloroacetamide using sodium hydride followed by palladium catalyzed coupling with 2-borono-1H-pyrrole-1-carboxylic acid 1-tert-Bu ester and cyanation using

chlorosulfonyl isocyanate. The activity of I was evaluated in vitro using T47D cell proliferation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 14.9 up to 120.5 nM. I as progesterone receptor modulators should prove useful in the treatment of carcinomas such as but not limited to breast, colon and prostate.

Pharmaceutical compns. comprising I are disclosed.


IT 865669-00-7P 865670-00-4P 865670-06-0P
865670-54-8P 865670-59-3P 865670-61-7P
865670-62-8P 865671-67-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl dihydrobenzoxazepinone derivs. as progesterone receptor modulators)


RN 865669-00-7 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-(1,2,3,5-tetrahydro-5-methyl-2-oxo-5-phenyl-4,1-benzoxazepin-7-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 865670-00-4 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[5,5-bis(3-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]-5-cyano-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-06-0 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[5,5-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]-5-cyano-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 865670-54-8 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-(1,2,3,5-tetrahydro-2-oxo-5,5-diphenyl-4,1-benzoxazepin-7-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-59-3 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-1-methyl-2-oxo-4,1-benzoxazepin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-61-7 CAPLUS

CN 1H-Pyrrole-2-carbonitrile, 5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-1-methyl-2-oxo-4,1-benzoxazepin-7-yl]- (CA INDEX NAME)





RN 865670-62-8 CAPLUS

CN 1H-Pyrrole-2-carbonitrile, 1-methyl-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-1-methyl-2-oxo-4,1-benzoxazepin-7-yl]- (CA INDEX NAME)




RN 865671-67-6 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-2-oxo-4,1-benzoxazepin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L13 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:120907 CAPLUS Full-text
 DN 142:219318
 TI Preparation of benzoxazepine derivatives as squalene synthase inhibitors
 IN Marui, Shogo; Miki, Takashi; Miura, Shoutarou; Nishimoto, Tomoyuki;
 Nakada, Yoshihisa
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 239 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005012272 | A1 | 20050210 | WO 2004-JP11293 | 20040730 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004260757 | A1 | 20050210 | AU 2004-260757 | 20040730 |
| | CA 2534464 | A1 | 20050210 | CA 2004-2534464 | 20040730 |
| | JP 2005068138 | A | 20050317 | JP 2004-222658 | 20040730 |
| | EP 1650201 | A1 | 20060426 | EP 2004-748264 | 20040730 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | CN 1832934 | A | 20060913 | CN 2004-80022202 | 20040730 |
| | BR 2004013009 | A | 20061003 | BR 2004-13009 | 20040730 |
| | MX 2006PA01007 | A | 20060427 | MX 2006-PA1007 | 20060125 |
| | IN 2006KN00235 | A | 20070803 | IN 2006-KN235 | 20060131 |
| | NO 2006001009 | A | 20060502 | NO 2006-1009 | 20060301 |
| PRAI | JP 2003-285341 | A | 20030801 | | |
| | WO 2004-JP11293 | W | 20040730 | | |
| OS | MARPAT 142:219318 | | | | |
| GI | | | | | |



I

AB The title compds. I (ring A and ring B each represents an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl optionally substituted by

optionally substituted hydroxy; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, O, or S; X3 represents a bond or an optionally substituted divalent hydrocarbon group; and Y represents optionally esterified or amidated carboxy) are prepared. A process for preparing I is disclosed. Thus, (2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]methyl]-1,3-thiazol-5-yl]acetic acid was prepared in a multistep process from 2-(tert-butoxycarbonylamino)acetic acid and potassium monoethyl malonate. Compds. of this invention are said to show IC₅₀ values of $\leq 1 \mu\text{M}$ against squalene synthase. Formulations are given.

IT 839724-80-0P 839724-83-3P 839725-04-1P
839725-12-1P 839725-13-2P 839725-46-1P
841236-35-9P 841236-36-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839724-80-0 CAPLUS

CN Propanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-83-3 CAPLUS


CN Butanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-04-1 CAPLUS
 CN 4-Thiazolepropanenitrile, 2-[[(3R, 5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- α -[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-12-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-acetonitrile, 3-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 839725-13-2 CAPLUS
 CN 4,1-Benzoxazepine-3-ethanimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R, 5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-butananimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-
1,2,3,5-tetrahydro-N-hydroxy-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-,
(3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-35-9 CAPLUS


CN 4,1-Benzoxazepine-3-ethanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-
chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-,
(3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-36-0 CAPLUS
CN 4,1-Benzoxazepine-3-propanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-
7-chloro-5-(2,3-dimethoxyphenyl)- α -[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-,
(3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902194 CAPLUS Full-text
 DN 141:395590
 TI Preparation of benzoxazepine compounds as RFRP receptor antagonists
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi
 PA Takeda Chemical Industries Ltd., Japan
 SO PCT Int. Appl., 226 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004091628 | A1 | 20041028 | WO 2004-JP5406 | 20040415 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | JP 2004331659 | A | 20041125 | JP 2004-120246 | 20040415 |
| | EP 1623710 | A1 | 20060208 | EP 2004-727766 | 20040415 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | US 2007129348 | A1 | 20070607 | US 2005-553273 | 20051012 |
| PRAI | JP 2003-114313 | A | 20030418 | | |
| | WO 2004-JP5406 | W | 20040415 | | |
| OS | MARPAT 141:395590 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(:O)n, NR3; n = 0-2; R3 = H, (un)substituted hydrocarbon group, etc.; R1, R2 = H, (un)substituted hydrocarbon group, etc.] were prepared For example, reductive amination of compound trans-II·HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II·HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC50 value was <1 μM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.

IT 782466-03-9P 782466-05-1P 782466-07-3P
 782466-49-3P 782466-51-7P 782466-55-1P
 782466-61-9P 782467-32-7P 782467-34-9P
 782467-38-3P 782467-40-7P 782467-71-4P
 782467-77-0P 782467-85-0P 782468-11-5P
 782468-62-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)


CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Chemical structure of compound 10: A 3-fluorobenzyl group is attached to the nitrogen of a 2-oxo-1,3-dihydro-2H-benzothiazine-4-thione ring. The ring has a 4-chlorophenyl group at position 5 and a 3-(3-methoxy-4-(3-aminopropoxy)phenyl) group at position 2. A substituent R is at position 3.

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-49-3 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-51-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-55-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-61-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl](3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-32-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-34-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-38-3 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-40-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-71-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidinyl ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-77-0 CAPLUS

CN Carbamic acid, [3-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl](trifluoroacetyl)amino]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-85-0 CAPLUS

CN Carbamic acid, [2-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]amino]ethyl](3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-11-5 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-(2-fluorophenyl)methyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 782468-62-6 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 782466-09-5P 782466-11-9P 782466-13-1P
 782466-15-3P 782466-17-5P 782466-19-7P
 782466-21-1P 782466-23-3P 782466-25-5P
 782466-27-7P 782466-29-9P 782466-31-3P
 782466-33-5P 782466-35-7P 782466-37-9P
 782466-39-1P 782466-41-5P 782466-43-7P
 782466-45-9P 782466-47-1P 782466-53-9P
 782466-57-3P 782466-59-5P 782466-63-1P
 782466-65-3P 782466-81-3P 782466-83-5P
 782466-85-7P 782466-87-9P 782466-89-1P
 782466-91-5P 782466-93-7P 782466-95-9P
 782466-97-1P 782466-99-3P 782467-01-0P
 782467-03-2P 782467-05-4P 782467-07-6P
 782467-09-8P 782467-11-2P 782467-13-4P
 782467-15-6P 782467-17-8P 782467-19-0P
 782467-21-4P 782467-23-6P 782467-25-8P
 782467-28-1P 782467-30-5P 782467-36-1P
 782467-42-9P 782467-53-2P 782467-63-4P
 782467-69-0P 782467-73-6P 782467-75-8P
 782467-79-2P 782467-81-6P 782467-83-8P
 782467-87-2P 782467-89-4P 782467-91-8P
 782467-97-4P 782467-99-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-09-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(pentylamino)propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-11-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(phenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-13-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-5-[3-[3-[(2-furanylmethyl)amino]propoxy]-2-methoxyphenyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-15-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-thienylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-17-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-pyridinylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-19-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-21-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(1-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-23-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(4-phenylbutyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-25-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(4-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-27-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-29-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-31-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-33-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-35-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenylethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782466-37-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2E)-3-phenyl-2-propenyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 782466-39-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(4-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B


—OMe

RN 782466-41-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(3-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

— OMe

RN 782466-43-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(2-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-45-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3,4-dimethoxyphenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl


—OMe

RN 782466-47-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[3-[[2-(1H-indol-3-yl)ethyl]amino]propoxy]-2-methoxyphenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl



RN 782466-53-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-57-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(4-phenylbutyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-59-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[methyl(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-63-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-65-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-7-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-81-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-83-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-85-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-phenylethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-87-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-N-methyl-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-89-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-91-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782466-93-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-95-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N,N-diethyl-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-97-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-99-3 CAPLUS

CN Piperidine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-05-4 CAPLUS

CN Morpholine, 4-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 1 HCl

RN 782467-07-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(4-piperidinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-09-8 CAPLUS

CN 1,4'-Bipiperidine, 1'-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-11-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(2-aminoethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-13-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-15-6 CAPLUS

CN 4-Piperidinamine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-17-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hexahydro-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-19-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-1-(2,2-dimethylpropyl)-1,5-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-3-[2-oxo-2-(4-piperidinyl)ethyl]-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-21-4 CAPLUS

CN Glycine, N-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-23-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-(dimethylamino)propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R, 5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-25-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-28-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-30-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-36-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-42-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-63-4 CAPLUS

CN Piperazine, 1-[[(3R, 5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[(3R, 5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylanino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-73-6 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-79-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[3-[(phenylmethyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-81-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[3-[(2-phenylethyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-83-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[3-[(3-phenylpropyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-87-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[2-[(3-phenylpropyl)amino]ethyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-89-4 CAPLUS

CN Carbamic acid, [2-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-91-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[2-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-97-4 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-[2-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-99-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 782468-96-6 782469-00-5 782469-02-7
782469-04-9 782469-06-1 782469-52-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of
RFRP receptor)

RN 782468-96-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-
fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-
phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 782469-00-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-
fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[(2E)-3-phenyl-
2-propenyl]amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX
NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 782469-02-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782469-04-9 CAPLUS

CN Piperidine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-06-1 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 782468-13-7P 782468-15-9P 782468-17-1P
782468-19-3P 782468-21-7P 782468-23-9P
782468-27-3P 782468-29-5P 782468-31-9P
782468-50-2P 782468-56-8P 782468-58-0P
782468-60-4P 782468-68-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-13-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-15-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-nitrophenyl)sulfonyl](2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-17-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-19-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-21-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-phenyl-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl](3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-23-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-7-phenyl-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-27-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-29-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-31-9 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-50-2 CAPLUS

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-[3-[[(2-nitrophenyl)sulfonyl] (3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, α 1-(1,1-dimethylethyl) α 3-methyl ester, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-56-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidinyl ester, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-68-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[6-phenylhexyl)amino]methyl]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:648392 CAPLUS Full-text
 DN 141:190808
 TI Preparation of aromatic ring-fused cyclic compounds as TGR5 receptor agonists
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Miki, Takashi; Kawamata, Yuji; Oi, Satoru; Tawaraishi, Taisuke; Ishichi, Yuji; Hirohashi, Mariko
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 337 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004067008 | A1 | 20040812 | WO 2004-JP706 | 20040127 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | | |
| | CA 2514547 | A1 | 20040812 | CA 2004-2514547 | 20040127 |
| | JP 2004346059 | A | 20041209 | JP 2004-18643 | 20040127 |
| | EP 1591120 | A1 | 20051102 | EP 2004-705536 | 20040127 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | US 2006199795 | A1 | 20060907 | US 2005-543997 | 20051031 |
| PRAI | JP 2003-19272 | A | 20030128 | | |
| | JP 2003-124311 | A | 20030428 | | |
| | WO 2004-JP706 | W | 20040127 | | |
| OS | MARPAT 141:190808 | | | | |
| GI | | | | | |



AB It is intended to provide G protein-coupled receptor (TGR5) agonists containing fused ring compds. represented by the following general formula (I), salts or prodrugs thereof (wherein the ring A represents an optionally substituted aromatic ring; and the ring B represents a 5- to 8-membered ring having one or more substituents). Also disclosed are regulators for physiolo. functions involving TGR5, preventives and/or remedies for various diseases involving TGR5, cytokine production inhibitors, GLP-1 secretion promoters, insulin secretion promoters, appetite depressants, pancreas regenerants, promoters for pancreas β -cell differentiation or proliferation, insulin resistance improvers, or immunosuppressants. containing the compds. I. In particular disclosed are preventives and/or remedies containing the compds. I for heart failure, myocardial infarction, acute kidney failure, angina pectoris, arrhythmia, bronchial asthma, chronic obstructive pulmonary disease, arteriosclerosis, chronic articular rheumatism, diabetes, obesity, insulin secretion failure, pancreas fatigue, gastric ulcer, ulcerative colitis, allergy, osteoarthritis, erythematodes, or excessive immune reaction after transplant surgery. The compds. I are also useful for screening ligands, agonists, or antagonists of TGR5. Thus, 0.1 g 2-[trans-7-chloro-5-(3-formylphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide was reduced by NaBH₄ in MeOH at room temperature for 30 min to give 76 mg 2-[trans-7-chloro-5-(3-hydroxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide (II). II at 1 μ M increased the production of cAMP in CHO cells expressing human TGR5

by 128%. Pharmaceutical formulations containing specific compound I were also prepared

IT 737785-10-3P 737785-11-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,

cytokine production inhibitors and appetite depressants)

RN 737785-10-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 737785-11-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 737785-21-6P 737785-22-7P 737785-27-2P
737785-29-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,


cytokine production inhibitors and appetite depressants)

RN 737785-21-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-[3-

(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-[(2-fluorophenyl)methyl]-
1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-22-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-27-2 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-3-[2-oxo-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 737785-29-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 215186-85-9P 215186-86-0P 215186-87-1P
 215186-88-2P 215186-89-3P 737783-99-2P
 737784-24-6P 737784-27-9P 737784-29-1P
 737784-36-0P 737784-37-1P 737784-38-2P
 737784-39-3P 737784-40-6P 737784-41-7P
 737784-42-8P 737784-43-9P 737784-44-0P
 737784-80-4P 737784-81-5P 737784-82-6P
 737784-83-7P 737784-85-9P 737784-86-0P
 737784-87-1P 737784-88-2P 737784-89-3P
 737784-90-6P 737784-91-7P 737784-92-8P
 737784-93-9P 737784-94-0P 737784-95-1P
 737784-97-3P 737784-98-4P 737784-99-5P
 737785-00-1P 737785-02-3P 737785-03-4P
 737785-06-7P 737785-08-9P 737785-09-0P
 737785-12-5P 737785-13-6P 737785-16-9P
 737785-17-0P 737785-18-1P 737785-19-2P
 737785-20-5P 737785-23-8P 737785-24-9P
 737785-26-1P 737785-28-3P 737785-30-7P
 737785-31-8P 737785-32-9P 737785-33-0P
 737785-34-1P 737785-35-2P 737785-37-4P
 737785-38-5P 737785-39-6P 737785-40-9P
 737785-41-0P 737785-42-1P 737785-43-2P
 737788-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,


cytokine production inhibitors and appetite depressants)

RN 215186-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.






RN 215186-88-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[[[(methylamino)carbonyl]amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737783-99-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-(3-aminophenyl)-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-24-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[(1-oxopropyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-27-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[(1-oxobutyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-29-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-36-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-37-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-38-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-propyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-39-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-methyl-2-oxo-N-(phenylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-40-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-41-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclohexylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-42-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-phenylethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-43-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(1-methyl-1-phenylethyl)-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-44-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737784-80-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[(tetrahydro-2-

furanyl)methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-81-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[2-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-82-6 CAPLUS

CN Glycine, N-[[[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-83-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclopentylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-86-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclopropylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-87-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[2-(methylthio)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-88-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[2-(methylsulfonyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-90-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-N-[(2-bromophenyl)methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-91-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-chlorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-92-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-93-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2,6-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-94-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2,2,2-trifluoroethyl)-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737784-95-1 CAPLUS

CN Glycine, N-[[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,
rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-97-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-98-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-99-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-00-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-fluorophenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-02-3 CAPLUS

CN Acetamide, N-[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-03-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-amino-2-oxoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-06-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)-2-oxoethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-08-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-oxo-2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-09-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethoxy]-2-methoxyphenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-12-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-13-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-16-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-17-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-propyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-18-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737785-19-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-

2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-20-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-23-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-24-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-26-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-28-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[2,2-dimethyl-3-[(methylsulfonyl)oxy]propyl]-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-30-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-cyclohexyl-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-31-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-32-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(3-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737785-33-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Chemical structure of a substituted benzodiazepine derivative. The structure features a benzodiazepine core with a 4-(benzylcarbamoyl)phenyl group at position 2, a 4-chlorophenyl group at position 3, and a 2-(furan-2-ylmethyl)carbamoyl group at position 4. The nitrogen at position 1 is substituted with a 2-methylpropyl group (labeled CMe₃). The structure includes stereochemical indicators with 'R' and 'S' labels and a wedge bond.


CN Cyclohexanecarboxylic acid, 4-[[[5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-(4H-1,2,4-triazol-4-ylmethyl)phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-(1H-imidazol-1-ylmethyl)phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(6-methoxy-2-naphthalenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-40-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-
N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-quinolinylmethyl)-
, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737785-41-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-

1-(9H-fluoren-9-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-42-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[5-(2-methoxyphenyl)-2-furanyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-43-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-([2,3'-bithiophen]-5-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737788-77-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 215185-18-5 737785-15-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists, cytokine production inhibitors and appetite depressants)

RN 215185-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737785-15-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 737784-48-4P 737784-51-9P 737784-52-0P
 737784-54-2P 737784-56-4P 737784-60-0P
 737784-61-1P 737784-62-2P 737784-75-7P
 737784-76-8P 737784-77-9P 737784-78-0P
 737784-79-1P 737785-01-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,

cytokine production inhibitors and appetite depressants)

RN 737784-48-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-51-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-52-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-54-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-56-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-60-0 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-, 2,2-dimethylpropyl ester, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-61-1 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-, 2,2-dimethylpropyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-62-2 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-2,3-dihydro-2-oxo-3-[2-oxo-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-, 2,2-dimethylpropyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-75-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(6-methoxy-2-naphthalenyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-76-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-quinolinylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-77-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(9H-fluoren-9-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-78-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[3-(2-methoxyphenyl)-2-furanyl]methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-79-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([2,3'-bithiophen]-5-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-01-2 CAPLUS

CN Carbamic acid, [[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, 9H-fluoren-9-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:22711 CAPLUS Full-text

DN 138:83384

TI Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

IN Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 2003002147 | A1 | 20030109 | WO 2002-JP6495 | 20020627 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2451163 | A1 | 20030109 | CA 2002-2451163 | 20020627 |
| | AU 2002313277 | A1 | 20030303 | AU 2002-313277 | 20020627 |
| | JP 2003081873 | A | 20030319 | JP 2002-188133 | 20020627 |
| | EP 1407782 | A1 | 20040414 | EP 2002-738822 | 20020627 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2004204500 | A1 | 20041014 | US 2003-480707 | 20031211 |
| | US 2006241096 | A1 | 20061026 | US 2006-473560 | 20060623 |
| PRAI | JP 2001-197419 | A | 20010628 | | |
| | WO 2002-JP6495 | W | 20020627 | | |
| | US 2003-480707 | A3 | 20031211 | | |
| OS | MARPAT 138:83384 | | | | |
| AB | Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same. | | | | |
| IT | 189059-19-6 189060-37-5 189060-41-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase) | | | | |
| RN | 189059-19-6 CAPLUS | | | | |
| CN | 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:368342 CAPLUS Full-text

DN 136:359669

TI High-density lipoprotein-cholesterol level elevating agent

IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 2002038180 | A1 | 20020516 | WO 2001-JP9802 | 20011109 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2428669 | A1 | 20020516 | CA 2001-2428669 | 20011109 |
| | AU 2002012741 | A5 | 20020521 | AU 2002-12741 | 20011109 |
| | JP 2002205956 | A | 20020723 | JP 2001-344074 | 20011109 |
| | EP 1332763 | A1 | 20030806 | EP 2001-981043 | 20011109 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2004063750 | A1 | 20040401 | US 2003-416239 | 20030506 |
| PRAI | JP 2000-342607 | A | 20001109 | | |
| | WO 2001-JP9802 | W | 20011109 | | |

OS MARPAT 136:359669

AB Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined. Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared

IT 189059-19-6 189059-70-9 189060-37-5


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)

RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidiny)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidiny)ethyl]-, (3R,5S)- (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:935587 CAPLUS Full-text
 DN 136:69829
 TI Preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents
 IN Kori, Masakuni; Miki, Takashi; Nishimoto, Tomoyuki; Tozawa, Ryuichi
 PA Takeda Chemical Industries, Ltd, Japan
 SO PCT Int. Appl., 643 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001098282 | A1 | 20011227 | WO 2001-JP5347 | 20010622 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2413429 | A1 | 20011227 | CA 2001-2413429 | 20010622 |
| | AU 200174588 | A | 20020102 | AU 2001-74588 | 20010622 |
| | JP 2002080468 | A | 20020319 | JP 2001-189417 | 20010622 |
| | JP 2003064063 | A | 20030305 | JP 2002-233086 | 20010622 |
| | EP 1292585 | A1 | 20030319 | EP 2001-941174 | 20010622 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | BR 2001011835 | A | 20030429 | BR 2001-11835 | 20010622 |
| | HU 2003001301 | A2 | 20030828 | HU 2003-1301 | 20010622 |
| | US 2003078251 | A1 | 20030424 | US 2002-203524 | 20020809 |
| | ZA 2002009055 | A | 20031107 | ZA 2002-9055 | 20021107 |
| | MX 2002PA12481 | A | 20030606 | MX 2002-PA12481 | 20021216 |
| | NO 2002006164 | A | 20021220 | NO 2002-6164 | 20021220 |
| PRAI | JP 2000-190253 | A | 20000623 | | |
| | JP 2001-189417 | A3 | 20010622 | | |
| | WO 2001-JP5347 | W | 20010622 | | |
| OS | MARPAT 136:69829 | | | | |
| GI | | | | | |



AB Alkoxyphenyloxobenzoxazepineacetamides [I; R = (un)substituted 1-carboxyethyl, (un)substituted carboxyalkyl, sulfonylalkyl, (carboxycycloalkyl)alkyl, etc.; R1 = alkyl (un)substituted with alkanoyloxy or OH groups (if R = (un)substituted 1-carboxyethyl, alkyl, 4-carboxycyclohexylmethyl, or 4-carboxyphenylmethyl, then R1 must be substituted with a OH or alkanoyloxy group); R2 = lower alkyl; W = halogen] are prepared as squalene synthase inhibitors for the treatment of hyperlipidemia and the decrease of serum triglycerides and lipids. (3R, 4S)-I [R = Me(CH₂)₂SO₂; R1 = HOCH₂C(Me)₂CH₂; R2 = Me; W = Cl] (II) was prepared in 3 steps from hydroxyacid (III) by acetylation of the hydroxyl group with acetic anhydride, treatment of the acid with thionyl chloride in THF to generate the acid chloride in situ, and addition of the mixture to a solution of PrSO₂NH₂ in THF to provide the acetylated methoxyphenyloxobenzoxazepineacetamide I [R = PrSO₂; R1 = AcOCH₂C(Me)₂CH₂; R2 = Me; W = Cl]; hydrolysis of the acetoxy group with aqueous sodium hydroxide and ethanol provides II. Data for the inhibition of squalene synthase by I are given. Pharmaceutical compns. containing I [R = 3-(HO₂CCH₂CH₂)C₆H₄; R1 = HOCH₂CMe₂CH₂; R2 = Me; W = Cl] are specified.


IT 383667-47-8P 383667-74-1P 383672-30-8P
 383672-35-3P 383672-40-0P 383672-50-2P
 383672-67-1P 383672-82-0P 383672-88-6P
 383672-95-5P 383673-01-6P 383673-16-3P
 383674-95-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediates; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383667-47-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-74-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-30-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-35-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-40-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-50-2 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-67-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-82-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-88-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-95-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-01-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-16-3 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-95-1 CAPLUS


CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 383653-40-5P 383657-22-5P 383657-72-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)
 RN 383653-40-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383657-22-5 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383657-72-5 CAPLUS
 CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 383653-45-0P 383657-27-0P 383657-78-1P
 383660-26-2P 383660-32-0P 383660-38-6P
 383660-43-3P 383660-48-8P 383660-52-4P
 383660-57-9P 383660-62-6P 383660-67-1P
 383661-12-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide
 squalene synthase inhibitors as antihyperlipidemic and
 antihypercholesteremic agents)

RN 383653-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-
 chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(2-
 pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-27-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-
 dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-
 4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-78-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-26-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-32-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-38-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-43-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-48-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-52-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-57-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-62-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-67-1 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-12-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:565016 CAPLUS Full-text
 DN 135:137529
 TI Preparation of azepine derivatives as VLA-4 antagonists
 IN Ikegami, Satoru; Inoguchi, Kiyoshi; Fukui, Hideto; Sumita, Yuji; Maruyama, Tatsuya; Watanuki, Mitsuru
 PA Kaken Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001055121 | A1 | 20010802 | WO 2001-JP521 | 20010126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | JP 2000-20358 | A | 20000128 | | |
| OS | MARPAT 135:137529 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, alkyl, aryl; R2 = H, (CH3)3COCO; R3 = alkylene, divalent aromatic hydrocarbon derivs.; R4 = H, alkyl; X = aromatic hydrocarbon; heterocycle; m = 1, 2, 3; Y = N, O; Z = R8R7R6A1; A1 = CH2, SO2; R6 = alkylene, divalent arylalkane derivs.; R7 = CH2, CO; R8 = alkyl, arylalkyl] and salts are prepared Title compds. or salts of title compds. are used as the active ingredient in remedies having peroral absorbability and exhibiting VLA-4 antagonism. Thus, the title compound II was prepared and biol. tested for VLA-4 antagonism.


IT 351903-54-3P 351903-55-4P 352234-56-1P
 352234-57-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azepine derivs. as VLA-4 antagonists)

RN 351903-54-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-55-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352234-56-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-57-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 351894-20-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azepine derivs. as VLA-4 antagonists)

RN 351894-20-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, ethyl ester, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 351903-56-5P 351903-57-6P 351903-58-7P
351903-59-8P 351903-60-1P 351903-61-2P
352234-61-8P 352234-62-9P 352234-63-0P
352234-64-1P 352234-65-2P 352234-66-3P
352234-67-4P 352234-68-5P 352234-69-6P
352234-70-9P 352234-71-0P 352234-72-1P
352234-73-2P 352234-74-3P 352234-82-3P
352234-83-4P 352234-93-6P 352234-94-7P
352234-95-8P 352235-02-0P 352235-03-1P

352235-04-2P 352235-05-3P 352235-06-4P
 352235-07-5P 352235-08-6P 352235-09-7P
 352235-10-0P 352235-11-1P 352235-12-2P
 352235-13-3P 352235-14-4P 352235-15-5P
 352235-20-2P 352235-21-3P 352235-22-4P
 352235-23-5P 352235-24-6P 352235-25-7P
 352235-26-8P 352235-27-9P 352235-28-0P
 352235-29-1P 352235-30-4P 352235-31-5P
 352235-32-6P 352235-33-7P 352235-34-8P
 352235-35-9P 352235-64-4P 352235-65-5P
 352235-66-6P 352235-67-7P 352235-68-8P
 352235-72-4P 352236-61-4P 352236-63-6P
 352236-65-8P 352236-67-0P 352236-69-2P
 352236-71-6P 352236-73-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azepine derivs. as VLA-4 antagonists)

RN 351903-56-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-57-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-58-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2S)-2-
[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-
methylpentyl]-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-59-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-
phenyl-1-[[3-[[[4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl
]methyl]-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-60-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2R)-2-
[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-
methylpentyl]-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-61-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2R)-2-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-methylpentyl]-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352234-61-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methoxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352234-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[[[(2-fluorophenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel-

1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[(4-carboxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-64-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(3-methoxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-65-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-66-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[3-methylphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-67-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-
oxobutyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 352234-68-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[5-[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-
oxopentyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 352234-69-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-2-oxo-
5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxopropyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-71-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-[[[hydroxy(phenylmethyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-72-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)



Relative stereochemistry.



RN 352234-73-2 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-[[[(2-methylphenyl)amino]carbonyl]-4-piperidinyl]carbonyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 352234-74-3 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-
 [[(2-methylphenyl)amino]carbonyl]-3-piperidinyl]carbonyl]amino]phenyl]meth
 yl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-82-3 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-


phenyl-1-[[3-[[3-(3-pyridinylcarbonyl)benzoyl]amino]phenyl]methyl]-,
(3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 352234-83-4 CAPLUS
CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[3-(2-pyridinylcarbonyl)benzoyl]amino]phenyl]methyl]-,
(3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 352234-93-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-(1H-indol-5-ylcarbonyl)benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-,
(3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-94-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-(1H-indol-2-ylcarbonyl)benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-95-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-(1H-indol-3-ylcarbonyl)benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-02-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[2-methoxyphenyl]acetyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-03-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dichlorobenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-04-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[3-[[[4-(benzoylamino)phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-05-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dimethylbenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-06-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dimethoxybenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[3-[[[4-[(2-benzothiazolylcarbonyl)amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-08-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[3-[[[4-(acetamido)phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-09-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]benzoyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-10-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-(2-naphthalenylcarbonyl)-4-piperidinyl]carbonyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-11-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[1-(phenylsulfonyl)-4-piperidinyl]carbonyl]amino]phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-12-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[1-(phenylsulfonyl)-3-piperidinyl]carbonyl]amino]phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 352235-13-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[4-[[[(1E)-2-phenylethenyl]sulfonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



Chemical structure of compound 10, a thiazolidine derivative. The structure shows a thiazolidine ring with a phenyl group (Ph) at the 2-position, a carboxylic acid group (HO₂C) at the 4-position, and a benzyl group at the 3-position. The thiazolidine ring is connected via a carbonyl group to a trans-alkene, which is further connected to a benzyl group.

| | | |
|----|--|--------|
| RN | 352235-15-5 | CAPLUS |
| CN | 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[(2E)-1,4-dioxo-4- [(1,2,3,4-tetrahydro-1-naphthalenyl)amino]-2-butenyl]amino]phenyl]methyl]- 1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME) | |


Relative stereochemistry.
Double bond geometry as shown.



RN 352235-20-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-fluoro-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-21-3 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-fluoro-5-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352235-22-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352235-23-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352235-24-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-25-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-26-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[hydroxy(phenylmethyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-27-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-28-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[2-bromo-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-29-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[2-methoxy-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-30-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-(dimethylamino)-5-[[[3-methoxy-4-[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-31-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[5-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-2-(1-pyrrolidinyl)phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-32-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[4-chloro-3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-33-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[2-methyl-3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-34-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 352235-35-9 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[4-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352235-64-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-65-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-

5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-66-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[(4-carboxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-67-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[(4-carboxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-68-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-72-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352236-61-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[2-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]ethyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-63-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[3-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]propyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-65-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[4-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]butyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-67-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[3-methoxy-4-[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]cyclohexyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-69-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[1-[[3-methoxy-4-[[(phenylamino)carbonyl]amino]phenyl]acetyl]-3-pyrrolidinyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352236-71-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[(3R)-1-[[3-methoxy-

4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-piperidinylmethyl]-2-oxo-5-phenyl-, (3S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-73-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[(3R)-1-[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-piperidinylmethyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:224390 CAPLUS Full-text
 DN 134:252365
 TI Preparation of oxazinobenzoxazepineacetates and analogs as squalene
 synthetase inhibitors
 IN Hayward, Cheryl M.; Scully, Douglas A.
 PA Pfizer Inc., USA
 SO U.S., 44 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 6207664 | B1 | 20010327 | US 1999-441339 | 19991116 |
| PRAI | US 1998-109939P | P | 19981125 | | |
| OS | MARPAT 134:252365 | | | | |
| GI | | | | | |




AB Title compds. [I; R = (un)substituted Ph or -naphthyl; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3 = CO2H, alkoxycarbonyl, CONH2, etc.; R4 = alk(en)yl, cycloalkylmethyl, Ph, etc.; Z = O, S, CH2; Z1 = O or S] were prepared (no data). Thus, (1R,7S,9R)-I [R = C6H3(OMe)2-2,3, R1 = 5-Me, R2 = H, R3 = CO2H, R4 = CMe3, Z1 = Z2 = O] was prepared starting from 3-tert-butyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazine and 2,3-(MeO)2C6H3CHO.

IT 331635-30-4P 331635-35-9P 331635-38-2P
 331635-44-0P 331635-50-8P 331635-51-9P
 331635-52-0P 331635-54-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxazinobenzoxazepineacetates and analogs as squalene synthetase inhibitors)

RN 331635-30-4 CAPLUS

CN 3-Pyrrolidinamine, 1-[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-35-9 CAPLUS

CN 3-Pyrrolidinamine, 1-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-38-2 CAPLUS

CN 8H-1,4-Oxazino[2,3,4-jk][4,1]benzoxazepine-6-acetamide, N-(2-aminoethyl)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-, (3R,6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 331635-44-0 CAPLUS

CN Benzeneacetic acid, α -[[[3-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-

oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]methylamino]propyl]methylamino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-50-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-51-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 4-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-52-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 6-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-54-2 CAPLUS

CN 8H-1,4-Oxazino[2,3,4-jk][4,1]benzoxazepine-6-acetamide, N-(6-aminohexyl)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-, (3R,6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:709062 CAPLUS Full-text

DN 129:330745

TI Preparation of 4,1-benzoxazepines as somatostatin agonists.

IN Mabuchi, Hiroshi; Suzuki, Nobuhiro; Miki, Takashi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 377 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 9847882 | A1 | 19981029 | WO 1998-JP1797 | 19980420 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2285664 | A1 | 19981029 | CA 1998-2285664 | 19980420 |
| | AU 9868545 | A | 19981113 | AU 1998-68545 | 19980420 |
| | JP 11209356 | A | 19990803 | JP 1998-109869 | 19980420 |
| | EP 979227 | A1 | 20000216 | EP 1998-914096 | 19980420 |
| | EP 979227 | B1 | 20051116 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | AT 309993 | T | 20051215 | AT 1998-914096 | 19980420 |
| | US 6352982 | B1 | 20020305 | US 1999-403066 | 19991014 |
| PRAI | JP 1997-103138 | A | 19970421 | | |
| | JP 1997-319545 | A | 19971120 | | |
| | WO 1998-JP1797 | W | 19980420 | | |
| OS | MARPAT 129:330745 | | | | |
| GI | | | | | |



AB Title compds. [I; A = atoms to form a (substituted) (hetero)aromatic ring; B = (substituted) (hetero)aromatic ring; Z = (substituted) cyclic group, linear hydrocarbon group; R1 = H, (substituted) hydrocarbyl, heterocycllyl; R2 = (substituted) amino; D = bond, (substituted) divalent hydrocarbyl; E = bond, CON(Ra), N(Ra)CO, N(Rb)CON(Rc), N(Rd)CO2, N(Re)SO2, CO2, N(Rf), O, S, SO, SO2, N-carboxypiperidin-4-yl, N-carboxypiperazin-4-yl; Ra-Rf = H, (substituted) hydrocarbyl; G = bond, divalent (substituted) hydrocarbyl; L = divalent group; R2B = (substituted) non-aromatic condensed N-heterocycllyl; X = H2, O, S; dotted line = optional double bond; Y = N when dotted line = double bond, or O, NR4, S, SO, SO2; R4 = H, (substituted) hydrocarbyl, acyl; when dotted line = single bond], were prepared Thus, 3,5-trans-N-(2-fluorobenzyl)-5-(3-

aminomethylphenyl)-1-(4-biphenylmethyl)- 7-chloro-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide hydrochloride (multistep preparation given) at 3 mg/kg i.p. in rats reduced plasma growth hormone concns. from 92 ng/mL (controls) to 11.2 ng/mL.

IT 215185-08-3P 215185-09-4P 215185-12-9P
215185-13-0P 215185-14-1P 215185-17-4P
215185-18-5P 215185-23-2P 215185-27-6P
215185-28-7P 215185-29-8P 215185-30-1P
215185-31-2P 215185-32-3P 215185-33-4P
215185-34-5P 215185-35-6P 215185-36-7P
215185-37-8P 215185-38-9P 215185-39-0P
215185-40-3P 215185-41-4P 215185-42-5P
215185-47-0P 215185-48-1P 215185-49-2P
215185-50-5P 215185-51-6P 215185-52-7P
215185-53-8P 215185-54-9P 215185-56-1P
215185-59-4P 215185-60-7P 215185-63-0P
215185-64-1P 215185-65-2P 215185-66-3P
215185-71-0P 215185-72-1P 215185-73-2P
215185-74-3P 215185-75-4P 215185-76-5P
215185-77-6P 215185-78-7P 215185-79-8P
215185-80-1P 215185-81-2P 215185-82-3P
215185-83-4P 215185-84-5P 215185-85-6P
215185-86-7P 215185-87-8P 215185-88-9P
215185-89-0P 215185-90-3P 215185-91-4P
215185-92-5P 215185-93-6P 215185-94-7P
215185-96-9P 215185-99-2P 215186-02-0P
215186-05-3P 215186-06-4P 215186-08-6P
215186-11-1P 215186-12-2P 215186-14-4P
215186-16-6P 215186-22-4P 215186-24-6P
215186-25-7P 215186-26-8P 215186-29-1P
215186-30-4P 215186-33-7P 215186-34-8P
215186-38-2P 215186-41-7P 215186-42-8P
215186-43-9P 215186-49-5P 215186-50-8P
215186-53-1P 215186-54-2P 215186-55-3P
215186-56-4P 215186-62-2P 215186-66-6P
215186-68-8P 215186-70-2P 215186-72-4P
215186-74-6P 215186-76-8P 215186-78-0P
215186-80-4P 215186-82-6P 215186-83-7P
215186-84-8P 215186-85-9P 215186-86-0P
215186-87-1P 215186-88-2P 215186-89-3P
215186-90-6P 215186-91-7P 215186-92-8P
215186-93-9P 215186-94-0P 215186-95-1P
215186-96-2P 215186-97-3P 215186-98-4P
215187-00-1P 215187-02-3P 215187-05-6P
215187-07-8P 215187-09-0P 215187-11-4P
215187-13-6P 215187-14-7P 215187-16-9P
215187-18-1P 215187-19-2P 215187-23-8P
215187-24-9P 215187-27-2P 215187-30-7P
215187-32-9P 215187-34-1P 215187-38-5P
215187-40-9P 215187-44-3P 215187-45-4P
215187-48-7P 215187-49-8P 215187-55-6P
215187-56-7P 215187-57-8P 215187-58-9P
215187-61-4P 215187-62-5P 215187-64-7P
215187-65-8P 215187-67-0P 215187-68-1P
215187-69-2P 215187-70-5P 215187-75-0P
215187-76-1P 215187-77-2P 215187-78-3P
215187-81-8P 215187-82-9P 215187-88-5P
215187-89-6P 215187-90-9P 215187-91-0P
215187-92-1P 215187-93-2P 215187-94-3P
215187-95-4P 215187-96-5P 215187-97-6P


215187-98-7P 215187-99-8P 215188-00-4P
 215188-01-5P 215188-02-6P 215188-03-7P
 215188-04-8P 215188-05-9P 215188-08-2P
 215188-09-3P 215188-16-2P 215188-17-3P
 215188-19-5P 215188-20-8P 215188-21-9P
 215188-22-0P 215188-25-3P 215188-26-4P
 215188-30-0P 215188-31-1P 215188-33-3P
 215188-34-4P 215188-38-8P 215188-39-9P
 215188-42-4P 215188-43-5P 215188-45-7P
 215188-46-8P 215188-49-1P 215188-50-4P
 215188-52-6P 215188-53-7P 215188-55-9P
 215188-56-0P 215188-60-6P 215188-82-2P
 215188-87-7P 215188-88-8P 215188-89-9P
 215188-90-2P 215188-95-7P 215188-96-8P
 215188-97-9P 215188-98-0P 215189-05-2P
 215189-06-3P 215189-11-0P 215189-12-1P
 215189-13-2P 215189-14-3P 215189-20-1P
 215189-21-2P 215189-22-3P 215189-23-4P
 215189-24-5P 215189-25-6P 215189-26-7P
 215189-27-8P 215189-28-9P 215189-29-0P
 215189-30-3P 215189-31-4P 215189-37-0P
 215189-38-1P 215189-39-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215185-08-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-09-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5S)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-12-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-13-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


RN 215185-18-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-23-2 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215185-27-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[2-(2-fluorophenyl)ethyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-28-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-chlorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-29-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-30-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2,4-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-31-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-32-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-33-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-N-methyl-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-34-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 215185-35-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-36-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-37-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[[2-(fluoromethyl)phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-38-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2,6-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(1H-indol-3-ylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-40-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-(cyclohexylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-41-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 215185-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 215185-47-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 215185-48-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[3,5-bis(trifluoromethyl)phenylmethyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215185-49-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-N-[3,4,5-trimethoxyphenylmethyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215185-50-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-(diphenylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-51-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-([1,1'-biphenyl]-2-ylmethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-

tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N,1-bis([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-53-8 CAPLUS


CN Benzoic acid, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215185-54-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-7-(3-phenylpropoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-56-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)acetyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-59-4 CAPLUS

CN Benzeneacetamide, N-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-fluoro-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-60-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-

oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-(2-methylpropoxy)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-63-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-64-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-(2-methylpropoxy)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-65-2 CAPLUS

CN Urea, N-[[(3R, 5R)-5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-N'-[(2-fluorophenyl)methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-66-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[(phenylmethyl)amino]methyl]phenyl]-, monohydrochloride, (3R, 5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-71-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-(1-piperidinylmethyl)phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-72-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[(methylamino)methyl]phenyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-73-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[(dimethylamino)methyl]phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-74-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenylpropyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-75-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(cyclohexylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-76-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-phenylethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-77-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-thienylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-78-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[(4-phenoxyphenyl)methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-79-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(3-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-80-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2-ethylbutyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-81-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-pentyl-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-82-3 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215185-83-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-84-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-2-ylmethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-85-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(1H-indol-3-ylmethyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 215185-86-7 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215185-87-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[[4-(nitrophenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215185-88-9 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(1-methyl-1H-indol-3-yl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 215185-89-0 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenylpropyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-90-3 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(cyclohexylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215185-91-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-phenylethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-92-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-93-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-94-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(3-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-96-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2-ethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-99-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-pentyl-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-02-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-05-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-06-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-2-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-08-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(1H-indol-3-ylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-11-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-12-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-14-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(1-methyl-1H-indol-3-yl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-16-6 CAPLUS

CN Carbamic acid, [[2-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-22-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-24-6 CAPLUS

CN Carbamic acid, [[2-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-25-7 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-26-8 CAPLUS
 CN Carbamic acid, [3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215186-29-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-(3-aminophenyl)-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-30-4 CAPLUS

CN Carbamic acid, [[4-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-33-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-34-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-38-2 CAPLUS


CN Carbamic acid, [2-[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215186-41-7 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



Ph


● HCl

RN 215186-42-8 CAPLUS


CN Carbamic acid, [[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215186-43-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




Ph

● HCl

RN 215186-49-5 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-50-8 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5S)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-53-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-54-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
 tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-55-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-
 [[4-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-
 benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 215186-56-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-62-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)methyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-66-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-68-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetyloxy)phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-72-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(3-phenoxypropoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-74-6 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenyl ester, monohydrochloride, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

||
O

RN 215186-76-8 CAPLUS

CN Acetic acid, [4-[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, ethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-78-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-80-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-[2-(acetyloxy)ethoxy]phenyl]methyl]-5-

[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-82-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-(2-hydroxyethoxy)phenyl]methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-83-7 CAPLUS

CN Acetic acid, [4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-84-8 CAPLUS

CN Acetic acid, [4-[[[(3R, 5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, methyl ester, monohydrochloride, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R, 5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-86-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[(methylsulfonyl)amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-87-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[trifluoroacetyl]amino]methyl]phenyl]-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-88-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[[[(methylamino)carbonyl]amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-90-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215186-91-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[(4-aminophenyl)methyl]-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


NH₂

RN 215186-92-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetylamino)phenyl]methyl]-5-[3-

(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-93-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-[(methylsulfonyl)amino]phenyl]methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 215186-94-0 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[[4-(dimethylamino)phenyl]methyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 215186-95-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[[4-(dimethylamino)phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-96-2 CAPLUS

CN Carbamic acid, [3-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]amino]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-97-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[[[3-aminopropyl]amino]methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 215186-98-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[[(aminoacetyl)amino]methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-00-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[(4-piperidinylcarbonyl)amino]methyl]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-02-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(3-aminopropoxy)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-05-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-07-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-09-0 CAPLUS


CN Piperazine, 1-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(4-fluorophenyl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-11-4 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(4-phenyl-1-piperidinylethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 215187-13-6 CAPLUS
 CN Piperidine, 1-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-phenyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-14-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[(triphenylmethyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 215187-16-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[(triphenylmethyl)amino]methyl]phenyl]-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-18-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-19-2 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-1-[[4-[(acetyloxy)methyl]phenyl]methyl]-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215187-23-8 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-[(acetyloxy)methyl]phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-24-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-

fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-(hydroxymethyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-27-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-30-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-32-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-34-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-40-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-8-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-44-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-8-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-45-4 CAPLUS


CN Carbamic acid, [1-[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 215187-48-7 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(1-amino-1-methylethyl)phenyl]-1-
([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-49-8 CAPLUS


CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 215187-55-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 215187-56-7 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-57-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-58-9 CAPLUS

CN Carbamic acid, [2-[2-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-61-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-62-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]-, phenylmethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215187-64-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-

chloro-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl)methyl]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-65-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-67-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-68-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(3-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-69-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(3-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-70-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-75-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-76-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-77-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-78-3 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-81-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-82-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-88-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-89-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-(3-chloropropoxy)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-90-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-(3-chloropropoxy)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-91-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(2-oxo-2-phenylethoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-92-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-7-(2-oxo-2-phenylethoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 215187-93-2 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-(2-hydroxyethoxy)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-94-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-(2-hydroxyethoxy)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215187-95-4 CAPLUS

CN Acetic acid, [[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-5-[3-[[[(1,1-

dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-96-5 CAPLUS

CN Acetic acid, [[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl

RN 215187-97-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(phenylmethoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-98-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-7-(phenylmethoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-99-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-(cyclohexylmethoxy)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-00-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-(cyclohexylmethoxy)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 215188-01-5 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-[3-(1H-imidazol-1-yl)propoxy]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-02-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-[3-(1H-imidazol-1-yl)propoxy]-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 215188-03-7 CAPLUS

CN Acetic acid, [[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-5-[3-[[[(1,1-

dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-04-8 CAPLUS
 CN Acetic acid, [[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl

RN 215188-05-9 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-08-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-09-3 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-16-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[2-(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-7-(3-phenylpropoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





PAGE 1-A



RN 215188-17-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-19-5 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




● HCl


RN 215188-20-8 CAPLUS
CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4'-hydroxy[1,1'-biphenyl]-4-yl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 215188-21-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4'-hydroxy[1,1'-biphenyl]-4-yl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-22-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[(4-fluorophenyl)methyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215188-25-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-26-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[3-(4-hydroxyphenyl)propyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-30-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[3-(4-hydroxyphenyl)propyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-31-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-[3-(4-hydroxyphenyl)propoxy]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-33-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-[3-(4-hydroxyphenyl)propoxy]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215188-34-4 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-[[4-(acetylamino)phenyl]methyl]-7-chloro-3-

[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-38-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetlamino)phenyl]methyl]-5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-39-9 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-

benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-42-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-
2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-43-5 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-1-[[4-(diethylamino)phenyl]methyl]-
3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-
4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester,

rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

Net₂

RN 215188-45-7 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-1-[[4-(diethylamino)phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




NEt₂

●₂ HCl


RN 215188-46-8 CAPLUS

CN Carbamic acid, [[3-[7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenyl-2-propenyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 215188-49-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenyl-2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215188-50-4 CAPLUS

CN Carbamic acid, [4-[2-[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]ethyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-52-6 CAPLUS

CN Carbamic acid, [4-[2-[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]ethyl]phenyl]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-53-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-55-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-56-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



RN 215188-60-6 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-, (3R,5R)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 215188-59-3

CMF C29 H26 Cl F N4 O3 S


Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4





RN 215188-82-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[[3,4-bis(phenylmethoxy)phenyl]methyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 215188-87-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-[[3,4-bis(phenylmethoxy)phenyl]methyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-88-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[(3,4-dihydroxyphenyl)methyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-89-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[(3,4-dihydroxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-90-2 CAPLUS


CN Carbamic acid, [[4-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 215188-95-7 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl


RN 215188-96-8 CAPLUS
 CN Carbamic acid, [[4-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215188-97-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-98-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5S)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-4-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-05-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[5-(aminomethyl)-2-methoxyphenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
 tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-06-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-
 2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[2-(phenylmethoxy)phenyl]methyl]-
 4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 215189-11-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[2-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-12-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(2-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-13-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(2-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-14-3 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 5-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-3,4-dihydro-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-(1,2,3,4-tetrahydro-5-isoquinolinyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-21-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-N-(1-methylethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215189-23-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-24-5 CAPLUS

CN Pyrrolidine, 1-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-25-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-3-[2-[(2-methoxyphenyl)amino]-2-oxoethyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-26-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-N-(2-methoxyphenyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-27-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-(cyclohexylamino)-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-28-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-cyclohexyl-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-29-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(2-thiazolylamino)ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-30-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-N-2-thiazolyl-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-31-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(trifluoromethyl)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-37-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215189-38-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-

tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215189-39-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

Ph

IT 215189-41-6P 215189-42-7P 215189-43-8P
215189-44-9P 215189-45-0P 215189-47-2P

215189-48-3P 215189-49-4P 215189-50-7P


215189-56-3P 215299-94-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215189-41-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-42-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetylamino)phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-43-8 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-[(methylsulfonyl)amino]phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215189-44-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215189-47-2 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(1-amino-1-methylethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215189-48-3 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-49-4 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-

biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-50-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-(1,2,3,4-tetrahydro-5-isoquinolinyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-56-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215299-94-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 215189-52-9



RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215189-52-9 CAPLUS

CN Acetic acid, [4-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 215185-26-5P 215185-43-6P 215185-44-7P
 215185-45-8P 215185-57-2P 215185-58-3P
 215185-62-9P 215187-36-3P 215187-63-6P
 215187-74-9P 215187-87-4P 215188-14-0P
 215188-15-1P 215188-29-7P 215188-32-2P
 215188-35-5P 215188-36-6P 215188-37-7P
 215188-44-6P 215188-51-5P 215188-57-1P
 215188-58-2P 215189-36-9P 215189-54-1P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215185-26-5 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-43-6 CAPLUS
 CN L-Leucine, N-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215185-44-7 CAPLUS
 CN L-Leucine, N-[[[(3S,5S)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215185-45-8 CAPLUS

CN L-Leucine, N-[[[(3S,5S)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215185-57-2 CAPLUS


CN Carbamic acid, [[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, 9H-fluoren-9-ylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-58-3 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-(aminomethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-62-9 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-(2-methylpropoxy)-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



PAGE 1-A




PAGE 2-A

RN 215187-36-3 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-methoxy-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 215187-63-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-[[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]methyl]-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-74-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[2-[4-(phenylmethoxy)phenyl]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-87-4 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[(tetrahydro-2H-pyran-2-yl)oxy]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[(tetrahydro-2H-pyran-2-yl)oxy]-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-

fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-29-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[3-[4-(phenylmethoxy)phenyl]propyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-32-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[3-[4-(phenylmethoxy)phenyl]propoxy]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-35-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

NO2

RN 215188-36-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1-[(4-aminophenyl)methyl]-7-chloro-5-[3-[1-[[1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215188-37-7 CAPLUS
 CN Carbamic acid, [1-[3-[(3R,5R)-1-[(4-aminophenyl)methyl]-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215188-44-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[4-(diethylamino)phenyl]methyl]-5-[3-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215188-51-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-[2-[4-[[[(phenylmethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester,


(3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215188-57-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-, ethyl ester (CA INDEX NAME)



RN 215188-58-2 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)- (CA INDEX NAME)



RN 215189-36-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-54-1 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 9H-fluoren-9-ylmethyl ester, rel- (9CI)
(CA INDEX NAME)



Relative stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:180583 CAPLUS Full-text
 DN 128:230397
 TI Preparation of 4,1-benzoxazepin-2-one derivatives and their uses
 IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki;
 Sugiyama, Yasuo
 PA Takeda Chemical Industries, Ltd., Japan
 SO U.S., 105 pp., Cont.-in-part of U.S. Ser. No. 195,131, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 5726306 | A | 19980310 | US 1994-338163 | 19941109 |
| | US 5885979 | A | 19990323 | US 1997-852292 | 19970507 |
| PRAI | JP 1992-99541 | A | 19920420 | | |
| | JP 1992-339947 | A | 19921221 | | |
| | US 1993-49455 | B1 | 19930420 | | |
| | US 1994-195131 | B2 | 19940209 | | |
| | JP 1994-244136 | A | 19941007 | | |
| | US 1994-338163 | A3 | 19941109 | | |
| OS | MARPAT 128:230397 | | | | |
| GI | | | | | |



AB Title compds. I (R = halogen; R1 = H, benzyl, alkyl, alkynyl, etc.; R2 = H, alkyl, Ph, heterocyclic, etc.; R3 = H, alkyl, Ph, heterocyclic, etc.; X = bond, spacer with chain length of 1-7 atoms; Y = carboxyl, alkoxy carbonyl, hydroxyl, amino group, Ph, carbamoyl group, etc.) and salts are prepared from condensation of II with 5-oxo-tetrahydro-2-furancarboxyl chloride and ClCO(Z)nCOOR4 ((Z)n = (CH2)3, CHCl(CH2)2, trans-CH:CH, etc.; R4 = H, Et, etc.). Title compds. I are useful for inhibiting squalene synthetase and fungal growth, and which are useful for treating or preventing hyperlipidemia in oral tablets or injections.

IT 152910-60-6P 152910-62-8P 152910-64-0P
 152910-66-2P 204505-84-0P 204505-91-9P
 204505-93-1P 204506-56-9P 204585-65-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

(preparation of benzoxazepinone derivs. and their uses)

RN 152910-60-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-
dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1H-tetrazol-5-yl)phenyl]-,
trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-62-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-
dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[4-(1H-tetrazol-5-yl)phenyl]-,
trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-64-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-
tetrahydro-1-(1-methylethyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-66-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 204505-84-0 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-91-9 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-93-1 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204506-56-9 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-65-9 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 152908-11-7P 152908-33-3P 152908-55-9P
 152908-56-0P 152911-35-8P 204505-94-2P
 204505-95-3P 204506-04-7P 204585-56-8P
 204585-57-9P 204585-58-0P 204585-66-0P
 204586-80-1P 204586-81-2P 204586-82-3P
 204586-83-4P 204586-85-6P 204586-88-9P
 204586-89-0P 204587-08-6P 204717-30-6P
 204717-32-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzoxazepinone derivs. and their uses)

RN 152908-11-7 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-33-3 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-55-9 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-56-0 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152911-35-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-,
trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 204505-94-2 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-95-3 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204506-04-7 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-56-8 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-57-9 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-58-0 CAPLUS

CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-66-0 CAPLUS


CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 204586-80-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, hydrazide (CA INDEX NAME)




RN 204586-81-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 204586-82-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 204586-83-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-amino-3-oxopropyl)-7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



RN 204586-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo- (CA INDEX NAME)




RN 204586-88-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[3-(dimethylamino)propyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 204586-87-8


CMF C27 H35 Cl2 N3 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 204586-89-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 204587-08-6 CAPLUS


CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204585-56-8

CMF C29 H25 Cl2 N3 O5


Absolute stereochemistry.



CM 2

CRN 107-92-6


CMF C4 H8 O2



RN 204717-30-6 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204717-32-8 CAPLUS
 CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 204717-31-7
 CMF C36 H31 Cl2 N3 O5

Absolute stereochemistry.



CM 2


CRN 107-92-6
 CMF C4 H8 O2



IT 152910-61-7P 152910-63-9P 152910-65-1P
 152910-67-3P 152911-36-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzoxazepinone derivs. and their uses)
 RN 152910-61-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(3-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans-

(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-63-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(4-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-65-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152910-67-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 152911-36-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-
1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:21418 CAPLUS Full-text
 DN 128:75386
 TI Preparation of benzoxazepinone derivs. as squalene synthetase inhibitors
 IN Bell, Andrew Simon; Hamanaka, Ernest Seiichi; Hayward, Cheryl Myers;
 Scully, Douglas Alan; Stammen, Blanda Luzia Christa
 PA Pfizer Inc., USA
 SO Eur. Pat. Appl., 42 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 814080 | A1 | 19971229 | EP 1997-304225 | 19970617 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | US 5965553 | A | 19991012 | US 1997-874089 | 19970612 |
| | CA 2208174 | A1 | 19971220 | CA 1997-2208174 | 19970618 |
| | JP 10059953 | A | 19980303 | JP 1997-162353 | 19970619 |
| PRAI | US 1996-19894P | P | 19960620 | | |
| OS | MARPAT 128:75386 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to certain benzoxazepinones and benzothiazepinones of Formula I; X = O, S(O), or SO₂; R₁, R₂, R₂₀ = H, halo, OH, CF₃, C₁-4 alkyl, etc; R₄ = C₁-4 alkenyl, C₁-7 alkyl, C₃-4 cycloalkylmethyl, C₁-7 alkenyl, het(C₁-6)alkyl wherein het is a 4-7 member (un)saturated heterocycle containing independently 1 - 3 O, N, or S atoms; Z = CO₂H, C₁-4 alkoxy carbonyl, mono-N or di-N,N-(C₁-4)alkylaminocarbonyl, NHCO, cyano or HONHCO] useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents. Thus, II was fermented with Streptomyces griseus in IOWA Medium to give 2.7 mg of III in 11% process yield.

IT ~~200567-79-9P~~ ~~200567-80-2P~~ ~~200567-86-8P~~
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzoxazepinone derivs. as squalene synthetase inhibitors for treatment of diseases)
 RN 200567-79-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[3-(dimethylamino)-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-5-(1-naphthalenyl)-2-oxo-, trans- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 200567-80-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[2,2-dimethyl-3-(4-morpholinyl)propyl]-1,2,3,5-tetrahydro-5-(1-naphthalenyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 200567-86-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1,2,3,5-tetrahydro-1-[4-(2-methyl-1H-imidazol-1-yl)butyl]-5-(1-naphthalenyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:317788 CAPLUS Full-text

DN 126:293368

TI Benzoxazepine compounds, their production and use as lipid lowering agents

IN Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 112 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 9710224 | A1 | 19970320 | WO 1996-JP2596 | 19960912 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2231052 | A1 | 19970320 | CA 1996-2231052 | 19960912 |
| | CA 2231052 | C | 20071113 | | |
| | AU 9669442 | A | 19970401 | AU 1996-69442 | 19960912 |
| | JP 09136880 | A | 19970527 | JP 1996-242378 | 19960912 |
| | JP 3479796 | B2 | 20031215 | | |
| | EP 862562 | A1 | 19980909 | EP 1996-930365 | 19960912 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | CN 1196052 | A | 19981014 | CN 1996-196892 | 19960912 |
| | CN 1072649 | B | 20011010 | | |
| | EP 1097928 | A1 | 20010509 | EP 2000-126672 | 19960912 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | AT 202774 | T | 20010715 | AT 1996-930365 | 19960912 |
| | ES 2158344 | T3 | 20010901 | ES 1996-930365 | 19960912 |
| | PT 862562 | T | 20011130 | PT 1996-930365 | 19960912 |
| | ZA 9702134 | A | 19990604 | ZA 1997-2134 | 19970312 |
| | US 6110909 | A | 20000829 | US 1998-43265 | 19980312 |
| | US 6613761 | B1 | 20030902 | US 2000-587947 | 20000606 |
| | JP 2001097963 | A | 20010410 | JP 2000-323310 | 20001018 |
| | JP 4021612 | B2 | 20071212 | | |
| | GR 3036707 | T3 | 20011231 | GR 2001-401564 | 20010926 |
| | US 2004072819 | A1 | 20040415 | US 2003-606152 | 20030624 |
| | US 2007117787 | A1 | 20070524 | US 2006-638066 | 20061212 |
| | JP 2007332154 | A | 20071227 | JP 2007-210503 | 20070810 |
| PRAI | JP 1995-235457 | A | 19950913 | | |
| | EP 1996-930365 | A3 | 19960912 | | |
| | JP 1996-242378 | A3 | 19960912 | | |
| | WO 1996-JP2596 | W | 19960912 | | |
| | ZA 1997-2134 | A | 19970312 | | |
| | US 1998-43265 | A3 | 19980312 | | |
| | US 2000-587947 | A1 | 20000606 | | |
| | JP 2000-323310 | A3 | 20001018 | | |
| | US 2003-606152 | B1 | 20030624 | | |
| OS | MARPAT 126:293368 | | | | |
| GI | | | | | |




- AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10⁻⁹ M.
- IT 189059-83-4P 189059-90-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylbenzoxazepinones as hypolipemic agents)
- RN 189059-83-4 CAPLUS
- CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- RN 189059-90-3 CAPLUS
- CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 189058-50-2P 189058-52-4P 189058-63-7P
 189058-64-8P 189059-40-3P 189059-42-5P
 189059-62-9P 189059-63-0P 189059-64-1P
 189059-94-7P 189059-95-8P 189060-41-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of arylbenzoxazepinones as hypolipemic agents)
 RN 189058-50-2 CAPLUS
 CN L-Asparagine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-
 dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189058-52-4 CAPLUS
 CN L-Glutamine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-
 dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,
 methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-63-7 CAPLUS

CN L-Histidine, N-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-64-8 CAPLUS

CN L-Tryptophan, N-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-40-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,

(3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-64-1 CAPLUS

CN 1H-Tetrazole-1-propanenitrile, 5-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-94-7 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-95-8 CAPLUS

CN 4-Piperidineacetone nitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-90-0P 189058-92-2P 189059-03-8P
 189059-04-9P 189059-11-8P 189059-12-9P
 189059-13-0P 189059-14-1P 189059-16-3P
 189059-17-4P 189059-18-5P 189059-19-6P
 189059-20-9P 189059-21-0P 189059-22-1P
 189059-23-2P 189059-39-0P 189059-41-4P
 189059-49-2P 189059-50-5P 189059-70-9P
 189059-77-6P 189060-37-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-90-0 CAPLUS

CN L-Asparagine, N2-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-92-2 CAPLUS

CN L-Glutamine, N2-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-03-8 CAPLUS

CN L-Histidine, N-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-04-9 CAPLUS

CN L-Tryptophan, N-[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-11-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 189059-12-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-(4-morpholinyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-13-0 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-piperidinyl)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-14-1 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-piperidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-16-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-17-4 CAPLUS

CN 4-Piperidinamine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N,N-dimethyl-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(3,4-dihydro-2(1H)-isoquinolinyl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-

1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-20-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(4-morpholinyl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-21-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-pyrrolidiny)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-22-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-23-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-41-4 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-49-2 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-50-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-1H-tetrazol-5-yl-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-70-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidiny)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-77-6 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:14595 CAPLUS Full-text

DN 126:59976

TI Preparation of benzothiazepinones as cholecystokinin antagonists

IN Yukimasa, Hidefumi; Miki, Takashi

PA Takeda Chemical Industries Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | JP 08259447 | A | 19961008 | JP 1995-66180 | 19950324 |
| PRAI | JP 1995-66180 | | 19950324 | | |
| OS | MARPAT 126:59976 | | | | |

GI For diagram(s), see printed CA Issue.

AB The title compds. I [ring A = (un)substituted benzene ring, etc.; R1 - R3 = H, (un)substituted hydrocarbon; X = bond, etc.; ring B = (un)substituted Ph, etc.; Z = O, etc.] are prepared In an in vitro test, the title compound II (preparation given) at 0.1 μ M gave 80% [3H]-CCK-8 binding inhibition.


IT 184881-95-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazepinones as cholecystokinin antagonists)

RN 184881-95-6 CAPLUS


CN Urea, N-[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-N'-(3-methylphenyl)-, (3R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1994:164246 CAPLUS Full-text
 DN 120:164246
 TI 4,1-Benzoxazepines as squalene synthase inhibitors and their use in the
 treatment of hypercholesteremia and as fungicides
 IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki
 PA Takeda Chemical Industries, Ltd., Japan
 SO Eur. Pat. Appl., 194 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 567026 | A1 | 19931027 | EP 1993-106276 | 19930417 |
| | EP 567026 | B1 | 20030326 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | SG 82630 | A1 | 20010821 | SG 1999-3981 | 19930417 |
| | AT 235474 | T | 20030415 | AT 1993-106276 | 19930417 |
| | AU 9337003 | A | 19931021 | AU 1993-37003 | 19930419 |
| | AU 659543 | B2 | 19950518 | | |
| | CA 2094335 | C | 19931021 | CA 1993-2094335 | 19930419 |
| | CA 2094335 | A1 | 19931021 | | |
| | NO 9301433 | A | 19931021 | NO 1993-1433 | 19930419 |
| | NO 304520 | B1 | 19990104 | | |
| | RU 2145603 | C1 | 20000220 | RU 1993-5332 | 19930419 |
| | CN 1083481 | A | 19940309 | CN 1993-106358 | 19930420 |
| | CN 1044237 | B | 19990721 | | |
| | JP 06239843 | A | 19940830 | JP 1993-117857 | 19930420 |
| | JP 3283628 | B2 | 20020520 | | |
| | HU 71482 | A2 | 19951128 | HU 1993-1164 | 19930420 |
| PRAI | JP 1992-99541 | A | 19920420 | | |
| | JP 1992-339947 | A | 19921221 | | |
| OS | MARPAT 120:164246 | | | | |
| GI | | | | | |



AB The titled compds. I [R1 = H, (un)substituted hydrocarbon group; R2, R3 = H, (un)substituted lower alkyl, (un)substituted Ph or aromatic heterocyclic group; X = direct bond, Z1-7 bridging group; Y = optionally esterified or thioesterified carboxyl group, (un)substituted OH, (un)substituted NH2, (un)substituted Ph, (un)substituted carbamoyl, etc.; ring A may be optionally substituted], which demonstrate inhibition of pathogenic fungal growth and inhibition of the enzyme squalene synthetase, are prepared and I-containing formulations presented. Thus, the Et ester of N-[(3-R,5-S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo-1,2,3,5- tetrahydro-4,1-benzoxazepine-3-

acetylaminocetate was hydrolyzed in NaOH solution, producing N-[(3R,5S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo- 1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]aminoacetic acid (II). II demonstrated 50% inhibitory concentration against human squalene synthetase of 0.06×10^{-7} M.

IT 152910-61-7F 152910-63-9F 152910-67-3P
152910-73-1F


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of benzoxazepine fungicides and squalene synthase inhibitors)

RN 152910-61-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(3-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-63-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(4-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-67-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-73-1 CAPLUS

CN 4,1-Benzoxazepine-3-propanal, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, α -(hydroxyhydrazone), trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




IT 152907-99-8P 152908-00-4P 152908-01-5P
 152908-02-6P 152908-03-7P 152908-04-8P
 152908-07-1P 152908-11-7P 152908-27-5P
 152908-30-0P 152908-33-3P 152908-55-9P
 152908-56-0P 152908-75-3P 152908-76-4P
 152910-21-9P 152910-22-0P 152910-23-1P
 152910-24-2P 152910-25-3P 152910-27-5P
 152910-28-6P 152910-60-6P 152910-62-8P
 152910-64-0P 152910-66-2P 152911-35-8P
 152911-36-9P 152984-64-0P 152984-65-1P
 152984-66-2P 152984-68-4P 152984-72-0P
 152984-73-1P 152984-74-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and squalene synthase inhibitory activity and fungicidal activity of)

RN 152907-99-8 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, methyl ester, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-00-4 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, (3R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-01-5 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-02-6 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-03-7 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-04-8 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152908-07-1 CAPLUS

CN L-Tryptophan, N-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-

(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-11-7 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-27-5 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-30-0 CAPLUS

CN L-Tryptophan, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-33-3 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-55-9 CAPLUS

CN Glycine, N-[[[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-56-0 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152908-75-3 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]carbonyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-76-4 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]carbonyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152910-21-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, hydrazide, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-22-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, 2,2-dimethylhydrazide, trans-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-23-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-yl)-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152910-24-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-amino-3-oxopropyl)-7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152910-25-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-27-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[3-(dimethylamino)propyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-28-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidiny)ethyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-60-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1H-tetrazol-5-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-62-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[4-(1H-tetrazol-5-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-64-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 152910-66-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




Relative stereochemistry.



| | | |
|----|--|--------|
| RN | 152984-64-0 | CAPLUS |
| CN | L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, (3R-trans)- (9CI) (CA INDEX NAME) | |


Absolute stereochemistry.



RN 152984-65-1 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 152984-66-2 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152984-68-4 CAPLUS


CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)-, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152984-67-3

CMF C36 H31 Cl2 N3 O5


Absolute stereochemistry.



CM 2

CRN 107-92-6


CMF C4 H8 O2



RN 152984-72-0 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152984-73-1 CAPLUS

CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152984-74-2 CAPLUS

CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 152910-65-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of benzoxazepine fungicides and squalene synthase inhibitors)

RN 152910-65-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




=> d 12; d 17; d 110; d his; log y
L2 HAS NO ANSWERS
L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L7 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.
L7 QUE ABB=ON PLU=ON L6

L10 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.
L10 QUE ABB=ON PLU=ON L9

(FILE 'REGISTRY' ENTERED AT 23:12:29 ON 17 JAN 2008)

DEL HIS Y
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 2 S L2
L4 14 S L2 FUL

FILE 'CAPLUS' ENTERED AT 23:13:17 ON 17 JAN 2008

L5 1 S L4

FILE 'REGISTRY' ENTERED AT 23:14:48 ON 17 JAN 2008

L6 STRUCTURE UPLOADED
L7 QUE L6
L8 50 S L7
L9 STRUCTURE UPLOADED
L10 QUE L9
L11 45 S L10
L12 871 S L10 FUL

FILE 'CAPLUS' ENTERED AT 23:16:45 ON 17 JAN 2008
L13 15 S L12

FILE 'STNGUIDE' ENTERED AT 23:18:53 ON 17 JAN 2008

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.18 | 449.11 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -12.80 |

STN INTERNATIONAL LOGOFF AT 23:20:47 ON 17 JAN 2008